Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

QLT Inc.

Status and phase: Completed; Phase 1

Conditions: Healthy Human Volunteers

Treatments: Drug: QLT091001

Study type: Interventional

Funder types: Industry

Identifiers

NCT00765427

RET HV 01

Details and patient eligibility

About

Healthy volunteer subjects will receive retinoid QLT091001 once-daily for 7 days for safety observation.

Enrollment: 18 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects with ECG within normal limits and normal blood pressure and resting heart rate

Exclusion criteria

• Subjects with any clinically important abnormal physical finding at screening.
• Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of baseline.
• Female subjects who are either pregnant or lactating.